Literature DB >> 8539072

[Clinical pharmacokinetics of azithromycin].

E Singlas1.   

Abstract

The bioavailability of azithromycin is approximately 37%. Concomitant administration of oral azithromycin with food significantly decreases by 50% drug bioavailability. Following a single oral 500 mg dose, peak plasma concentrations of about 0.35-0.45 mg/l are attained within approximately 2 hours. With a 500 mg oral dose on day 1, followed by 250 mg daily on days 2 to 5, peak and through plasma concentrations on day 5 are around 0.25 and 0.05 mg/l respectively. These low plasma concentrations are the consequence of extensive and rapid distribution from plasma to tissues. Plasma protein binding is low, less than 50% at plasma concentrations obtained with the usual dosage regimen. Apparent volume of distribution is very large, 25 to 35 l/kg. Azithromycin is mainly eliminated unchanged in the faeces via biliary excretion and transintestinal secretion. Urinary excretion is a minor elimination route: about 6% and an oral dose and 12% of an intravenous dose are recovered unchanged in urine. The mean terminal elimination half-life of azithromycin is 2 to 4 days. The pharmacokinetics of azithromycin is not significantly altered in elderly subjects and in patients with mild to moderate renal or hepatic insufficiency.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8539072

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  14 in total

1.  Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin.

Authors:  Masami Sugie; Emiko Asakura; Ying Lan Zhao; Shoko Torita; Masayuki Nadai; Kenji Baba; Kiyoyuki Kitaichi; Kenji Takagi; Kenzo Takagi; Takaaki Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 2.  The Role of Macrolides in Chronic Rhinosinusitis (CRSsNP and CRSwNP).

Authors:  Gretchen M Oakley; Richard J Harvey; Valerie J Lund
Journal:  Curr Allergy Asthma Rep       Date:  2017-05       Impact factor: 4.806

Review 3.  The role of advanced generation macrolides in the prophylaxis and treatment of Mycobacterium avium complex (MAC) infections.

Authors:  G W Amsden; C A Peloquin; S E Berning
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 4.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 5.  Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes.

Authors:  C A Peloquin
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

Review 6.  Environmental impacts of mass drug administration programs: exposures, risks, and mitigation of antimicrobial resistance.

Authors:  Joanna K Konopka; Pranab Chatterjee; Connor LaMontagne; Joe Brown
Journal:  Infect Dis Poverty       Date:  2022-06-30       Impact factor: 10.485

Review 7.  BDDCS, the Rule of 5 and drugability.

Authors:  Leslie Z Benet; Chelsea M Hosey; Oleg Ursu; Tudor I Oprea
Journal:  Adv Drug Deliv Rev       Date:  2016-05-13       Impact factor: 15.470

8.  The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients.

Authors:  Nijad Bakhshaliyev; Mahmut Uluganyan; Asim Enhos; Erdem Karacop; Ramazan Ozdemir
Journal:  J Electrocardiol       Date:  2020-08-11       Impact factor: 1.438

Review 9.  Emerging therapeutics in the management of COVID-19.

Authors:  Asim Kichloo; Michael Albosta; Akshay Kumar; Michael Aljadah; Mohamed Mohamed; Zain El-Amir; Farah Wani; Shakeel Jamal; Jagmeet Singh; Akif Kichloo
Journal:  World J Virol       Date:  2021-01-25

10.  An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia.

Authors:  Andang Miatmoko; Eryk Hendrianto; Deya Karsari; Aristika Dinaryanti; Nora Ertanti; Igo Syaiful Ihsan; Disca Sandyakala Purnama; Tri Pudy Asmarawati; Erika Marfiani; Alfian Nur Rosyid; Prastuti Asta Wulaningrum; Herley Windo Setiawan; Imam Siswanto; Ni Nyoman Tri Puspaningsih
Journal:  PLoS One       Date:  2021-06-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.